Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.34 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8491907 | 0.77 | CNR1 (0.34) | HTTCNR1 | |
| SCHEMBL13670601 | 0.75 | HTT (0.43) | HTTCES2CES1PKMSMN1; SMN2 | |
| SCHEMBL8827233 | 0.75 | HTT (0.38) | HTTCES2CES1PKMSMN1; SMN2 | |
| SCHEMBL2345633 | 0.75 | FFAR1 (0.43) | — | |
| SCHEMBL30572278 | 0.75 | CAPN1 (0.38) | CNR1 | |
| SCHEMBL23692883 | 0.73 | FASN (0.42) | HTTCES2CES1PKMSMN1; SMN2 | |
| SCHEMBL10752209 | 0.73 | ALDH1A1 (0.43) | CNR1PKMSMN1; SMN2 | |
| SCHEMBL7198078 | 0.73 | MAPT (0.53) | HTTCES1SMN1; SMN2 | |
| SCHEMBL7024101 | 0.71 | HTT (0.48) | HTTCES2CES1PKMSMN1; SMN2 | |
| SCHEMBL26976906 | 0.70 | HTR7 (0.52) | HTTCES2CES1PKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170042865-A1 | THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170042865-A1 | THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, CPT1A | HTT 24/4885SLC5A1 4405/4885SLC5A2 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.